Clinical Trial Update: A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of ASP4345 in schizophrenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• ASP4345

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED